Bucindolol bristol-myers squibb co.

IDrugs

Volumn 2, Issue 2, 1999, Pages 168-183

  Scatena, Roberta ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUCINDOLOL;

CONGESTIVE HEART FAILURE; DRUG METABOLISM; DRUG SYNTHESIS; HUMAN; HYPERTENSION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; MUSCLE WEAKNESS; PLASMA RENIN ACTIVITY; SHORT SURVEY; STRUCTURE ACTIVITY RELATION; VASODILATATION; VERTIGO;

EID: 0033035298     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (306)

1. Long-term (2 year) beneficial effects of β-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy Anderson JL, Gilbert EM, O'Connell JB, Renlund D, Yanowitz F. Murray M, Roskelley M, Mealey P, Volkman K, Deitchman D, Bristow M JAM COLL CARDIOL 1991 17 1373-1381
2. Calculating the end-systolic pressure-volume relation [letter, comment] Crottogini AJ, Willshaw P CIRCULATION 1991 831121-1123
3. β-Blocking agents with vasodilating action. Prichard BN J CARDIOVASC PHARMACOL 1992 19 Suppl 1 S1-S4
4. Therapy of idiopathic dilated cardiomyopathy with chronic β-adrenergic blockade. Gilbert EM, O'Connell JB, Bristow MR HEART VESSELS SUPPL 1991 6 29-39
5. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Bristow MR, Larrabee P, Muller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD CLIN INVEST 1992 70 S105-S113
6. β-Blockade with bucindolol in heart failure caused by ischémie versus idiopathic dilated cardiomyopathy Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR CIRCULATION 1991 84 2426-2441
7. Double blind study on IDC and ISCDC. Therapeutic comparison with intriguing results.
8. β-Blocking agents and positive inotropic agents in the therapy of chronic heart failure Erdmann E, Schwinger R, Bohm M J CARDIOVASC PHARMACOL 199016 S138-S144
9. Optimization of β-blockers1 pharmacology Tamargo J, Delpon E J CARDIOVASC PHARMACOL 199016 S10-S18
10. Pharmacological and clinical aspects of drug therapy in coronary heart disease: Clinical aspects of therapy with βadrenocéptor antagonists Prichard BNC ZKARDIOL1990 79 99-103
11. Experimental and'clinical pharmacology of carvedilol and other drugs combining vasodilation and β-adrenoceptor antagonism in a single molecule Strein K, Sponer G Z KARDIOL 19907989-98
12. Use of β-adrenergic blocking agents in congestive heart failure Krukemyer JJ CLIN PHARM1990 9 853-863
13. Bucindolol hydrochloride DRUGS FUTURE 199015 7 730
14. Usefulness of bucindolol in congestive heart failure PollockSG, Lystash J, Tedesco C, Craddock G, Smucker ML AM J CARDIOL 199066603-607
15. Effect of β-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield BA, Deitchman D, Brown M, Willard JE, Graybum PA CIRCULATION 1990 82473-483
16. Pathophysiological mechanisms underlying the effects of βadrenergic agonists and antagonists on functional capacity and survival in congestive heart failure Packer M CIRCULATION 1990 82 I-77-I-88
17. Clinical use of β-adrenoceptor blockade in systemic hypertension Nadelmann J, Frishman WH DRUGS 1990 39 862-876 /
18. Mechanism of action of bucindolol in human ventricular myocardium Hershberger RE, Wynn JR, Sundberg L, Bristow MR J CARDIOVASC PHARMACOL 199015 6 959-967
19. Highlights from the American Heart Association Syrop J HOSP THER199015 371 -390
20. Highlights from the 62nd scientific sessions of the American Heart Association DRUG THER 1990 20 79-81
21. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR AM J MED 1990 88223-229
22. Double blind study on IDC.
23. Trial alert Opie LH CARDIOVASC DRUGS THER 1989 3 795-796
24. High-performance liquid Chromatographie determination of β-adrenoceptor blocking agents in body fluids Soltes L BIOMED CHROMATOGR1989 3 139-152
25. Effects of Ca' antagonists and K'-channel activators on K'-induced contractions in the rat aorta Lawson K, Cavero I J AUTON PHARMACOL 1989 9 329-336
26. Which drug for what patient with heart failure, and when? Francis GS CARDIOLOGY 1989 76 374-383
27. Treatment of chronic heart failure Packer M LANCET 1992 340 92-95 -
28. Bucindolol, a β-blocker, decreased ventricular fibrillation and maintained mechanical function in a pig model of acute myocardial ischemia Muller CA, Opie LH, Pineda CA, Peisach M CARDIOVASC DRUGS THER 1992 6 233-237
29. Receptor pharmacology of carvedilol in the human heart ristow MR, Larrabee P, Minobe W, Roden R, Skert L, Klein J, Handwerger D, Port JD, Muller-Beckmann B J CARDIOVASC PHARMACOL 1992 19 Suppl 1 S68-S80
30. Are contraction and relaxation coupled in patients with and without congestive heart failure? Eichhorn EJ, Willard JE, Alvarez L, Kim AS, Glamann DB, Risser RC, Graybum PA CIRCULATION 1992 85 6 2132-2139
31. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes Bristow MR, Larrabee P, Muller Beckmann B, Minobe W, Roden R, Skert L, Klein J, Handwerger D, Port JD CLIN INVEST SUPPL 1992 70 S105-S113
32. Pharmacological profile of β-adrenoceptor blockers with vasodilating properties, especially carvedilol - Rationale for clinical use Sponer-G, Bartsch-W, Strein-K CLIN INVEST SUPPL 199270S20-S26
33. Dilated cardiomyopathy Sotos JG, Levin HR, Baughman KL CURR OPIN CARDIOL 1992 7 429-438
34. The paradox of β-adrenergic blockade for the management of congestive heart failure Eichhorn EJ AM J MED 199292527-538
35. Therapy of idiopathic dilated cardiomyopathy with chronic βadrenergic blockade Gilbert EM, O'Connell JB, Bristow MR HEART VESSELS 1991 6 29-39
36. Myopericardial disease in children Tripp ME CURR OPIN CARDIOL 1992 7 103-110
37. The evolving status of βblockade in the treatment of congestive heart failure Alvarez LG, Eichhorn EJ PRIM CARDIOL 1991 1728-29+32-34
38. New therapeutic strategies in chronic heart failure: Challenge of long-term β-blockade Hjalmarson A, Waagstein F EUR HEART J1991 1263-69
39. β-Adrenergic blockade in congestive heart failure: Answering the old questions Jessup M J AM COLL CARDIOL 1991 18 1067-1069
40. Defining the role of β-blockers in dilated cardiomyopathy Waagstein-F, Fu-L-X, Hjalmarson-A PRIM CARDIOL 1991 17 3436+41
41. Bucindolol hydrochloride DRUGS FUTURE 1991 16 7 652-653
42. Risks and benefits of the treatment of heart failure: Current status Moran JF DRUG SAF1991 6 277-284
43. β-Receptor antagonists in the treatment of heart failure Persson H, Erhardt L CARDIOVASC DRUGS THER 1991 5 589604
44. Newer β-blockers and the treatment of hypertension McAreavey D, Vermeulen R, Robertson JIS CARDIOVASC DRUGS THER 1991 5577-588
45. Introduction to focused section on new developments in β-blockade Fitzgerald JD CARDIOVASC DRUGS THER 1991 5 545-547
46. β-Blockers in cardiac failure Fowler MB CURR OPIN CARDIOL 1991 6368-372
47. Cardiovascular therapies in the 1990s. An overview Becker-RC, Gore-JM DHUGS1991 41 345-357
48. Update from the American heart association meetings Ratner SJ DRUGS TODA Y1991 27 65-68
49. Effects of bucindolol on neurohormonal activation in congestive heart failure Eichhorn EJ, McGhie AI, Bedotto JB, Corbett JR, Malloy CR, Hatfield BA, Deitchman D, Willard JE, Graybum PA AM J CARDIOL 1991 67 67-73
50. β-Adrenoceptor and cardiovascular effects of MJ 13105 (Bucindolol) in anesthetized dogs and rats Deitchman D, Perhach JL Jr, Snyder RW EUR J PHARMACOL 1980 61 263-277 Well-realized study on animal pharmacology.
51. Cardiovascular effects of bucindolol (MJ 13105) in conscious dogs Deitchman D, Byme JE, Snyder RW ARCH INT PHARMACODYN THER 1980 247 76-88
52. New antihypertensive agent (Bucindolol) Gates HF MEDJ AUST1980 2 224-225
53. Beneficial effects of bucindolol in a canine model of pentobarbital-induced heart failure. Deitchman D, Snyder RW ARCH INT PHARMACODYN THER 1981 250 65-72
54. Studies in the rat on bucindolol, a new antihypertensive agent with beta-adrenoceptor blocking properties Gates HF, Stoker LM, Stokes GS ARCH INT PHARMACODYN THER 1981 251 95-102
55. Bucindolol hydrochloride Weetman DF DRUGS FUTURE 1981 6405-407
56. Evidence for a direct vasodilator action of bucindolol, a new antihypertensive agent Hanson RC, Snyder RW, Deitchman D FED PROC1982 41 8051
57. Drugs blocking adrenoceptors Andersson KE ACTA MED SO4A/D19822129-17
58. Antihypertensive actions of an isomer of labetalol and other vasodilator-β-adrenoceptor blockers Baum T, Sybertz EJ FED PROC19B3 42 176-181
59. Synthesis of (13)C-bucindolol hydrochloride Dolak TM, Kreighbaum WE, Johnson PC, Covington RR J LABEL COMPD RADIOPHARM1983 20 1183-1187
60. β-Blockers Giudicelli JF, Witchitz S SEM HOP 1983 59 23952426
61. Comparison of the antihypertensive efficacy of bucindolol and propranolol Malini PL, Strocchi E, Ambrosioni E J HYPERTENS 19831 348-350
62. Stereospecificity in drug action. A source of errors in pharmacotherapy Ariens EJ NED TIJDSCHR GENEESKD 1984 128 404-407
63. Stereoselectivity in drug action. A source of errors in pharmacotherapy Ariens EJ PHARM WEEKBL 1984 119 177-181
64. Bucindolol, a β-adrenoceptor blocker with vasodilatory action: Its effect in systemic hypertension Rotmensch HH, Rocci ML Jr, Vlasses PH, et al AM J CARDIOL1984 54 353-356
65. Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure Uretsky BF, Generalovich T, Reddy PS, el al AM J CARDIOL 1984 54 357-362
66. The pharmacology of vasodilators Giudicelli JF LYON MEDITERR MED 1983 19 8275-8281
67. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology Ariens EJ EUR J CLIN PHARMACOL1984 26 663-668
68. Selectivity of the intrinsic sympathomimetic activity of the βadrenergic blocking drug bucindolol Left AR, Garrity ER, Munoz NM, et al J CARDIOVASC PHARMACOL 1984 6 5 859-866
69. Bucindolol: Effects on blood pressure, airways resistance and serum creatine phosphokinase Gill JS, Beevers DG EUR J CLIN PHARMACOL 1984 27 265-268
70. Pharmacology of bucindolol in isolated canine vascular smooth muscle Rimele TJ, Aarhus LL, Lorenz RR, et al J PHARMACOL EXP THER1984 231 317-325
71. Pharmacology of combined oβ-blockade I Louis WJ, McNeil JJ, Drummer OH DRUGS 1984 28 16-34
72. Peripheral hemodynamics under β-receptor blockade Overioack A, Stumpe KO, Muller HM, et al VERH DTSCH GES INN MED 1984 1759-1762
73. Comparative β-adrenoceptor blocking effect and pharmacokinetics of bucindolol and propranolol in man Maury M, Berdeaux A, Kher A, et al EUR J CUN PHARMACOL 1985 27 649-656
74. Short- and long-term studies of Bucindolol in mild to moderate hypertension: Efficacy, safety, and exercise responses Rosendorff C, Goodman C, Coull A J CUN PHARMACOL 1985 25 233-236 ;
75. The possible role of the ancillary properties of β-adrenoceptor antagonists in the management of angina pectoris Fitzgerald JD ACTA MED SCAND1985 217 120-141
76. Vasodilating β-adrenoceptor blocking drugs do not redistribute myocardial flow during acute coronary ligation in dogs Berdeaux A, Bonhenry C, Giudicelli JF EUR J PHARMACOL 1985112379-385
77. Structure and activity of cardiovascular agents Soudijn W PHARM WEEKBL 1985 120 710-721
78. Differential cardioprotective properties of the I- and denantiomers of bucindolol in a canine model of heart failure Weyl JD, Snyder RW, Hanson RC ARCH INT PHARMACODYN THER1985 275 4-12
79. Derivatives related to betaxolol with a and βadrenergic activities Leclerc G, Decker N, Schwarte J ARZNE1M1TTELFORSCHUNG 1985 35 1357-1367
80. A comparison of single doses of bucindolol and oxprenolol in hypertensive patients Webster J, Pétrie JC, Robb OJ, et al BR J CLIN PHARMACOL 1985 20 393-400
81. Bucindolol in essential hypertension Reid JL, Curzio J, Vincent J INT J CLIN PHARMACOL RES 1985 5 293-301
82. Role of a and βadrenoceptors in mechanism of action of various antihypertensive drugs Badia A, Vila E REV FARM CLIN EXP1985 2 161 -164
83. The pharmacokinetics of bucindolol and its major metabolite in essential hypertension Meredith PA, Kelman AW, McSharry DR, et al XENOBIOTICA 1985 15 979-985 Valuable pharmacokinetic study on bucindolol in hypertensive patients,
84. Bucindolol has serotonin and alpha -adrenoceptor blocking properties Marwood JF, Stokes GS J CAROIOVASC PHARMACOL 1985 7 Suppl 7 S67-S69
85. Stereochemlcal pitfalls in pharmacotherapy Ariens EJ, Mohr K DTSCHMED WOCHENSCHR1985 110 45 1741-1749
86. Bucindolol Gill JS, Beevers DG AM J CARDIOL 1985 56 10 704
87. Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers O'Connor PC, Finch MJ, Harron DWG, et al BR J CLIN PHARMACOL 1985 20 6 659-667
88. Therapy of chronic heart insufficiency with vasodilators Urbaszek W, Graf B Z GESAMTE INN MED IHRE GRENZGEB 198641375-80
89. Intrathecal injection of codeine, buprenorphine, tilidine, tramadol and nefopam depresses the tail-flick response in rats Bematzky G, Juma I EUR J PHARMACOL 1986 120 1 75-80
90. The effects of antihypertensive therapy on lipids Weinberger MH CARDIOVASC MED 1986 11 4 10-11
91. Studies on the vasodilator actions of bucindolol in the rat Marwood JF, Stokes GS CLIN EXP PHARMACOL PHYSIOL 1986 13 1 59-68
92. Determination of bucindolol and its major metabolites in plasma by capillary gas chromatography-mass spectrometry Bartek MJ, Kerns EH, Gammans RE, Gallo DG J CHROMATOGR B BIOMEDAPPL 1986 377 183-194
93. The effect of bucindolol on the airway function of asthmatics Puffin RE, Crocked AJ, Alpers JH EUR J CLIN PHARMACOL 1986 30 5 559-565
94. The effect of β-blockers on total peripheral resistance Man-in't-Ve!d AJ, Van Den Meiracker A, Schalekamp-MADH J CARDIOVASC PHARMACOL 1986 8 Suppl 4 S49-S60
95. Hemodynamic properties of bucindolol, a βadrenoreceptor blocking drug with vasodilator activity Ben N, Dryburgh L, Boyle C, Hawley C AM J CARDIOL 1986 57 8 678-681
96. Hypertension Vlasses PH AM J PHARM1985 157 9-22
97. In vitro characterization of the adrenoceptor activity of AY-28,925 Rimele TJ, Heaslip RJ, Lee DKH, Grimes D J PHARMACOL EXP THER1986 239 1 1 -8
98. New therapeutic concepts in the treatment of myocardial ischemia. Present and future medications Jaillon P ANN CARDIOL ANGEIOL 1986 35 7 BIS 453-458
99. The management of hypertension Prichard BNC, Owens CWI BRJ CLIN PHARMACOL 198621 Suppl 2 129S-142S
100. In vitro effects of β-adrenoceptor agonists and antagonists on the rat ovarian suspensory ligament Stanton HC, Dungan KW J PHARMACOL EXP THER 1986 239 2 591-596
101. Clinical pharmacokinetics of β-adrenoceptor antagonists. An update Riddell-JG, Harron-DWG, Shanks-RG CLIN PHARMACOKIN1987 12 5 305-320
102. Effect of β-blockers on vascular resistance in systemic hypertension Man-in-'t-Veld AJ AM J CARDIOL 1987 59 13 21F25F
103. Effect of bucindolol on plasma HDL cholesterol subfractions and other plasma lipids in essential hypertensive patients Lehtonen A, Tanskanen A, Temmerman J INT J CLIN PHARMACOL THER TOXICOL 1987 25 8 448-451
104. Study on positive effects of bucindolol on lipid metabolism, in particular on HDLs and apoprotein.
105. Efficacy of bucindolol in systemic hypertension KimuraS, DeQuattro V, Edmiston WA, Loo R, Thien S, Rigonan K, Deitchman D, Foti A AM J CARDIOL 1987 60 13 1083-1086
106. Hemodynamic effects during rest and exercise of bucindolol in hypertensive men Conner DP, Vlasses PH, Clement! RA, Oren A, Deitchman D, Ferguson RK J CLIN PHARMACOL 1987 27 4 300-303
107. Double-blind study on hypertensive patients.
108. Synthesis of indolyloxypropanolamines bearing the 2(1H-indol-3yl)-1,1-dimethylethyl group: Structure-activity studies and anti-hypertensive activity Wagnon J, Plouzane C, Tonnerre B, Demame H, Serre M, Lacour C, Gougat J, Gagnol JP, Gautier P EUR J MED CHEM1988 23 1 11-20
109. Risk-benefit of specific antihypertensive regimens: Relevance of metabolic and haemodynamic effects of o,blockers Reid JL, Curzio J, Elliott HL CLIN EXP PHARMACOL PHYSIOL 1988 15 3 185-190
110. Controlling hypertension via adrenoreceptors Cohen LS PRIM CARDIOL 1988 14 9 62-64
111. The management of acute poisoning due to βadrenoreceptor antagonists Critchley JAJH, Ungar A MED TOXICOL ADVERSE DRUG EXP 1989 4 1 32-45
112. Progress in antihypertensive therapy with a multipleaction drug Prichard BNC, Tomlinson B DRUGS 1988 36 Suppl. 6 20-25
113. Pathophysiological mechanisms underlying the effects of β-adrenergic agonists and antagonists on functional capacity and survival in congestive heart failure Packer M CIRCULATION 1990 82 2 Suppl I-77-I-88
114. The evolving status of beta blockade in the treatment of congestive heart failure Alvarez LG, Eichhorn EJ PRIM CARD1OL 1991 171228-29+32-34
115. Angiotensin-con verting enzyme inhibitors or vasodilators as therapy in chronic heart failure: A review of the trials Lindsay DC, Poole-Wilson PA J CARDIOVASC PHARMACOL 199219S45-S55
116. The use of β-blockade therapy in treatment of congestive heart failure Sobotka PA, Gunnar RM CLIN CARDIOL 199215630-635
117. Chronic β-adrenoceptor blockade in idiopathic dilated cardiomyopathy (clinical results) Sigmund M, Reineke T Z KARDIOL 1992 81 65-70
118. Pathophysiologic aspects and new therapeutic approaches for cardio-circulatory failure Peruzzi G, Di Nardo P, Raimondi G, Legramante JM, lellamo F, Massaro M, Bellegrandi F, Minien M, Pafi M, Castrucci F, Cassarino S, Bartoli M, Tallarida G CLIN TER 1992 141 339-372
119. β-Blockers in heart failure: Potential of carvedilol Fowler MB J HUM HYPERTENS1993 7 S62-S67
120. Pathophysiologic and pharmacologie rationales for clinical management of chronic heart failure with β-blocking agents Bristow MR AM J CARDIOL I99371 12C-22C
121. Controlled trials with β-blockers in heart failure: Metoprolol as the prototype Fowler MB AM J CARDIOL 1993 71 45C-53C
122. Effects of bucindolol in heart failure Eichhorn EJ AM J C4HDO.199371 65C-70C
123. Long-term"'(3-month) effects of a new β-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P JAM COLL CARDIOL 1993 21 1094-1100 Nebivolol therapy in heart failure.
124. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Bristow MR, Larrabee P, Muller Beckmann B, Minobe W, Roden R, Skeri L, Klein J, HandwergerD, Port JD CLIN INVEST199270 105-113
125. β-Blocking agents with vasodilating action. Prichard BN J CARDIOVASC PHARMACOL 199219 Suppl 1 S1-S4
126. Receptor pharmacology of carvedilol in the human heart Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD, Muller Beckmann B J CARDIOVASC PHARMACOL 199219 Supp! 1 S68-S80
127. Beneficial effects of longterm β-blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. Anderson J, Gilbert E, O'Connell J, Renlund D, Yanowitz F, Bartholomew M, Murray M, Mealey P, Volkman K, Bristow M JAM COLL CARDIOL 198913 117A
128. Improvement in contractile performance in patients with congestive failure by chronic β-blocker therapy with bucindolol. Eichom E J, Bedotto J, Hatfield B, Deitchman D, Graybum P A, Brown M, MalloyCCOTCC/MT/OA/198980 II117 /
129. β-Blockade with vasodilation improves congestive heart failure. Pollock SG, Lystash J C, Tedesco CL, Craddock G B, Smucker MLC/Ct;M77OA/19B980 11118
130. Improvement in diastolic performance in patients with congestive failure by chronic β-blocker therapy with bucindolol.
131. Eichom EJ, Bedotto JB, Hatfield B, Deitchman D, Graybum PA, Brawn M, Malloy C CIRCULATION 1989 80II276
132. Can response to β-blocker therapy in idiopathic dilated cardiomyopathy be predicted by baseline parameters? Gilbert EM, Mestroni L, Anderson JL, Woodley SL, Bristow MR CIRCULATION 198980 I1428
133. A multicenter, randomized trial of bucindolol vs. placebo.
134. Bristow MR, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Deitchman D, BUCINDOLOL STUDY GROUP (USA) CIRCULA TION1990 82 111674
135. Mechanism of action of carvedilol in human ventricular myocardium. Minobe W, Larrabee P, Bristow MR J AM COLL CARDIOL 199I 17250A
136. Do β-blocking agents improve left ventricular function in subjects with ischémie dilated cardiomyopathy? White M, Gilbert EM, Anderson JA, O'Connell JB, Olsen S, Renlund DG, Bristow MR JAM COLL CARDIOL 1993 21 2 Suppl A 115A
137. Pathophysiologic and pharmacologie rationales for clinical management of chronic heart failure with beta-blocking agents. Bristow MR AM J CARDIOL 1993 71 9 12C-22C
138. Metoprolol as the prototype. Fowler MB AM J CARDIOL 199371 945C-53C
139. Effects of bucindolol in heart failure. Eichom EJ AM J CARDIOL 1993 71 9 65C-70C
140. Down regulation of cardiac beta-1-adrenergic receptors by atypical beta-blocking agents. Bristow MR, Handwerger D, Klein J, Port JD CIRCULATION 1992 86 4 Suppl 1 I646
141. Down regulation of cardiac beta-1-adrenergic receptors by atypical beta-blocking agents. Bristow MR, Handwerger D, Klein J, Port JD CIRCULATION 1992 86 4 Suppl 1 I646
142. A possible role for vasodilators. Poole-Wilson PA INT J CARDIOL 1993 401 1-6
143. Mediation of most atypical effects by species homologs of the beta.3-adrenoceptor. Blin Nathalie, Nahmias Clara, Drumare MF, Strosberg AD BR J PHARMACOL 1994 112 3 911919
144. Structural and conformational features determining selective signal transduction in the βadrenergic receptor Blin Nathalie, Camoin Luc, Maigret Bernard, Strosberg Donny MOL PHARMACOL 1993 44 6 1094-1104
145. Licensing Information Bristol-Myers Squibb COMPANY COMMUNICATION 1994October
146. Dose-response of chronic β-blocker treatment In heart failure from either idiopathic dilated or ischémie cardiomyopathy. Bucindolol Investigators. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, et al CIRCULATION 19948941632-1642
147. Beta-blockers in heart failure: Promising or proved?
148. Doughty RN, MacMahon S, Sharpe N JAM COLL CARDIOL 1994 233814-821
149. Bucindolol hydrochloride. DRUGS FUTURE 1994 19 7 684
150. β-blockers for heart failure: Where are we now?. Gottlieb SS CURR OP/A/ CARDIOL 1994 9 3 295-300
151. Do β-blockers have a role in patients with congestive heart failure?. Eichhorn EJ CARDIOL CLIN 1994 12 1 133-142
152. β-Adrenergic blockade in patients with chronic heart failure: Issues and answers. Tecce MA, Jessup M PRIM CARDIOL 1994 20 1 33-35+37-38
153. The role of β-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Hjalmarson A, Waagstein F DRUGS 1994 47 S uppl 31 -40
154. β-Blockers in cardiac failure. Ertl G, Neubauer S, Gaudron P, Horn M, Hu K, Tian R, Krähe T EUR HEART J 1994 15 Suppl 16-24
155. Medical advances in the treatment of congestive heart failure. Armstrong PW. Moe GW CIRCULATION 1993 88 6 2941-2952
156. [Structure and function of the β,-adrenergic receptor]. STRUCTURE ET FONCTION DU RECEPTEUR -3-ADRENERGIQUE. Emorine L, Strosberg D MED SCI 1993 9 11 1228-1235
157. Bucindolol hydrochloride. DRUGS FUTURE 1993 18 7 653
158. Licensing information. Bristol-Myers Squibb COMPANY COMMUNICATION 1993 September 10
159. Interneuron finalizes acquisition of company with cardiovascular product scheduled for advanced clinical trials. INTERNEURON PHARMACEUTICALS PRESS RELEASE 1994 September 28
160. Intercardia, an Interneuron subsidiary names President and CEO. Interneuron Pharmaceutical PRESS RELEASE 1995 January 05
161. Interneuron Pharmaceuticals Inc ANNUAL REPORT1994
162. Optimism returns to heart failure R&D SCRIP 1995 2014 27
163. BEST trial with bucindolol begins SCRIP 1995 2017/18 31
164. Phase III clinical trial begins in heart failure with bucindolol, under development by Intercardia, an Interneuron subsidiary Intemeuron Pharmaceuticals Incorporated PRESS RELEASE 1995 April 10
165. Interneuron Pharmaceuticals Inc - Form 10Q, September 1994 Intemeuron Pharmaceuticals Inc FORM 10-K 1994 September 30
166. Bucindolol National Institute of Health, Dept of Veterans Affairs, Intemeuron Pharmaceuticals Inc CLIN TRIALS MONITOR 1995 4 6 P7
167. Interneuron's cardiovascular progress SCRIP 19952063 15
168. Astra Merck and Intercardia announce agreement to develop and market heart failure medication. Astra Merck Inc PRESS RELEASE 1995 December 5
169. Intercardia/Astra Merck to collaborate on β-blocker Bucindolol. FDC REPORTS PINK SHEET 1995 57 50 T&G-17 198692 Interneuron completes CPEC buy-out: SCRIP 1996 210212
170. Intercardia hunts for small-molecule free radical scavengers for lung disorders EMERGING PHARMACEUTICALS 19965212
171. Intercardia's bucindolol plans SOT/P19962110 9
172. Cardiac adrenergic receptor effects of carvedilol Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR EUR HEART J 1996 17 Suppl B 8-16
173. Receptor state and ligand efficacy [1]. Chidiac P TRENDS PHARMACOL SC11995 16 3 83-84
174. Interneuron Pharmaceuticals Inc ANNUAL REPORT 1995 December
175. Ongoing and planned clinical trials of antiarrhythmic drugs. Schron B, Friedman LM, Greene HL EXP OPIN INVEST DRUGS 1995 4 215-221
176. Pharmacological characteristics and species-related variations of β3-drenergic receptors. Pietri-Rouxel F, Strosberg AD FUNDAM CLIN PHARMACOL 1995 9 3 211 -218
177. Intercardia and Knoll announce agreement for international development of heart failure drug Intercardia Inc PRESS RELEASE 1996 December 19
178. Function and regulation of the β,-adrenoceptor. Strosberg AD, Pietri-Rouxel F TRENDS PHARMACOL SC1199617 10 373-381
179. Effects of several putative β,-adrenoceptor agonists on lipolysis in human omental adipocytes. Hoffstedt J, Lonnqvist F, Shimizu M, Blaak E, Amer P INT J OBESITY 1996 20 5 428-434
180. Company news in brief. SCRIP 1996 December 1114 230438 R&D pipeline. SCRIP 1996 December 11 22 231299 Company agreements. SCRIP 1997 219610
181. Treatment of end stage dilated cardiomyopathy. O'Connell JB, Moore CK, Waterer HC BR HEART J1994 72 6 Suppl S52-S56
182. Interneuron to boost stake in Intercardia SCRIP 1997 2209 11
183. [What is the choice of drug treatment for heart failure in 1996?]. LES TRAITEMENTS MEDICAMENTEUX DE L'INSUFFISANCE CARDIAQUE. QUEL CHOIX EN 1996?. Witchitz S, Arsenescu I. Pellerin D ANN CARDIOL ANGEIOL1996 45 8 445-452
184. SkyePharma enters deal with Intercardia SCRIP 1997 2219/207
185. β-Adrenergic blocking agents in the treatment of congestive heart failure: Mechanisms and clinical results. Doughty RN, Sharpe N ANNU REV MED 1997 48 103-114
186. β-Blockers in chronic heart failure: Paradox proven? Krum H MED JAUST199616410 581-582
187. Interneuron Pharmaceuticals announces second quarter fiscal 1997 results. Interneuron Pharmaceuticals. PRESS RELEASE 1997 May 06
188. [Turntable cardiology. Current discussion from the practice. Cardiovascular Winter Workshop at Gstaad, Switzerland, 1-8 February 1997]. DREHSCHEIBE KARDIOLOGIE. ACTUELLE
189. DISKUSSIONEN AUS DER PRAXIS. HERZ-KREISLAUF WINTERWORKSHOP, GSTAAD/SCHWEIZ, 1. BIS 8.2.1997. MUNCH MED WOCHENSCHR1997 139 15 Suppl 1-34
190. Effect of β-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials Heidenreich PA, Lee TT. Massie BM JAM COLL CARDIOL 1997 30 1 27-34
191. Interneuron Pharmaceuticals announces third quarter fiscal 1997 results'Intemeuron Pharmaceuticals Inc PRESS RELEASE 1997 August 12
192. Nearly 100 cardiovascular drugs in the pipeline, PhRMA reports. HOSP FORMUL 1997 32 7 672
193. Bucindolol hydrochloride DRUGS FUTURE 1997 22 7 780
194. There is life after Losec, says Astra SCRIP 1996 2192/3 22
195. Intercardia to acquire Transcell Technologies Intercardia Inc PRESS RELEASE 1997 November 5
196. Interneuron restructures subsidiaries SCRIP 1997 2284 6
197. [Severe mitral régurgitation with ejection fraction below 40%: Drug treatment is therapy of choice]. SCHWERE MITRALINSUFFIZIENZ BEI AUSWURFFRAKTION UNTER 40%: DIE MEDIKAMENTÖSE BEHANDLUNG IST DIE THERAPIE DER WAHL Rothlin ME SCHWEIZ MED WOCHENSCHR 1997127 49 2035-2039
198. [Drug therapy of congestive heart failure]. DIE MEDIKAMENTÖSE THERAPIE DER SCHWEREN HERZINSUFFIZIENZ. Kiowski W, Sutsch G, Fafo R, Schalcher CH, Brunner LAROCCAHP SCHWEIZ MED WOCHENSCHR 1997 127 49 2026-2034
199. Interneuron Pharmaceuticals Inc - Form 10Q, June 1997 FORM 10-Q1997 June
200. Interneuron Pharmaceuticals Inc: corporate profile Intemeuron Pharmaceuticals Inc COMPANY PROSPECTUS 1997
201. Interneuron Pharmaceuticals Inc - Form 10Q, 1997 Intemeuron Pharmaceuticals Inc FORM 10-Q 1997 March
202. Carvedilol and dose-related improvements in left ventricular function [10] (multiple letters). Ghali JK, Bristow MR, Gilbert EM, Abraham WT, Robertson AD, Chatterjee K, Stem L CIRCULATION 1997 96 8 2743-2744
203. Primary prevention of sudden cardiac death in heart failure: Will the solution be shocking? Uretsky BF, Sheahan RG J AM COLL CARDIOL 1997 30 7 1589-1597
204. [β-Blockade in the treatment of heart failure]. PLACE DES β-BLOQUANTS DANS LA THERAPEUTIQUE DE LA DECOMPENSATION CARDIAQUE. Kulbertus H MED HYG 1997 55 2173 1479-1482
205. Practical guidelines for initiation of β-adrenergic blockade in patients with chronic heart failure. Eichhorn EJ, Bristow MR AM J CARDIOL 1997 79 6 794-798
206. Modulation of human cardiac function through 4 βadrenoceptor populations. Kaumann AJ, Molenaar P NAUNYN SCHMIEDEBERG'S ARCH PHARMACOL1997 355 6 667-681
207. [β-Blockers in heart failure]. LES BETA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE. Vanhaecke J, Droogne W, Van CLEEMPUTJ, Van DEWERFF ANN CARDIOL ANGEIOL 1997 46 8 527-529
208. The role of β-blockers in left ventricular dysfunction and heart failure. Hjalmarson A, Kneider M, Waagstein F DRUGS 1997 54 4501-510
209. Management of congestive heart failure in primary care settings. Ahmed O COMPR THER1997 23 7 472-476
210. Carvedilol for heart failure: Renewed interest in β-blockers. Young JB CLEVEL CLINJMED 1997 64 8 415-422
211. [β-Adrenergic blockers in heart failure: Should they always be included in the therapeutic strategy? Arguments for]. BETABLOQUEANTES EN LA INSUFICIENCIA CARDIACA: DEBEN INCLUIRSE SIEMPRE EN LA ESTRATEGIA TERAPEUTICA? ARGUMENTOS A FAVOR. De TERESAE REV ESP CARD1OL 1997505300-303
212. Second- and third-generation β-blocking drugs in chronic heart failure. Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS, Lowes BD, Robertson AD, Larrabee P, Gilbert EM CARDIOVASC DRUGS THER 1997 11 1 291-1296
213. [β-Receptor blockers: Renaissance in the therapy of heart failure]. BETAREZEPTORENBLOCKER: RENAISSANCE IN DER THERAPIE DER HERZINSUFFIZIENZ. Klein W WIEN KLIN WOCHENSCHR1997 109 7 219-221
214. [β-Receptors and β-blockers in heart failure]. BETAREZEFTOREN UND BETABLOCKER BEI HERZINSUFFIZIENZ. MED MONATSSCHR PHARM 1997 20 6 146-148
215. [Pharmacological mechanisms in blood pressure normalization]. MECANISMOS FARMACOLOGICOS EN LA NORMALIZACION TENSIONAL. Serrano MOLINAJS, Serrano MOLINAMI REVLATCARDIOL EUROAMER1CANA 1997 18 4 130- : 137
216. β-Adrenoceptor blockers in chronic heart failure - A review. Krum H BR J CLIN PHARMACOL 1997 44 2 111 -118
217. 69th Scientific Session of the American Heart Association. 10-13 November 1996, New Orleans, Louisiana, USA. Danser AHJ, Maassen VanDenBrink A, Van Kesteren CAM EXP OPIN INVEST DRUGS 1997 6 1 87-90
218. [Use of β-blockers in current therapy and the prospect of their further development]. VYUZITIE β-BLOKATOROV V SUCASNEJ TERAPII A PERSPEKTIVY ICH D'ALSIEHO VYVOJA. Racanska E, Svec P FARM OBZ1997 66 3 63-66
219. Efficacy of β-blockers in idiopathic dilated cardiomyopathy and ischémie cardiomyopathy. Waagstein F AM J CARDIOL 1997 80 9 B 45J-49J
220. Do β-blockers have a role in the treatment of chronic heart failure?. Panfilov V. Olsson G EXP OPIN INVEST DRUGS 199761 23-29
221. Managing symptomatic heart failure in 1997: Strategies for the end- stage patient. McNamara D, Alvarez RJ, Rosenblum W, Murali S, Feldman A IM INT MED 1997 186 18-24
222. β-Blocker use in systolic heart failure and dilated cardiomyopathy. Hash TWII, Prisant LM J CLIN PHARMACOL 1997371 7-19
223. [Therapy of heart failure with β-blockers]. THERAPIE DER HERZINSUFFIZIENZ MIT .beta.-BLOCKERN?. Osterziel KJ. Dietz RZKARDIOL 1997 86 1 1-8
224. Studies on agents with vasodilator and β-blocking activities. IV. Seki T, Nakao T, Masuda T. Hasumi K, Gotanda K, Ishimori T, Honma S, Minami N, Shibata K, Yasuda K CHEM PHARMBULL 199644 11 2061-2069
225. β-Blocking agents in heart failure. Should they be used and how? Cleland JGF, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F EUR HEART J1996 17 11 1629-1639
226. [Therapy of heart failure: A new field of indication for β-blockers?]. THERAPIE DER HERZINSUFFIZIENZ. EIN NEUER INDIKATIONSBEREICH FUR BETABLOCKER?. THERAPIEWOCHE 1996 46 27 1515-1516
227. β-Adrenergic blockers and survival in heart failure. Pfeffer MA, Stevenson LW NEW ENGU MED 1996 334 21 1396-1397
228. [β-Blockers in chronic heart failure: Comment]. BETABLOCKER BEI CHRONISCHER HERZINSUFFIZIENZ. STELLUNGNAHMEN ZUM THEMA. INTERNIST 1996 37 12 12741279
229. β-Blockers in hypertensive and coronary heart disease. Goldstein S ARCH INTERN MED 1996 156 12 1267-1276
230. Meta-analysis of the use of low-dose β-adrenergic blocking therapy in idiopathic or ischémie dilated cardiomyopathy. Zarembski DG, Nolan JRPE, Slack MK, Lui CY AM J CARDIOL 1996 7714 1247-1250
231. [β-Blocking agents in heart failure: Time for another approach?] BETABLOCKER BEI HERZINSUFFIZIENZ: ZEIT ZUM UMDENKEN? Follath F SCHWEIZ MED WOCHENSCHR1996 126 18 747-749
232. Bucindolol hydrochloride. DRUGS FUTURE 1996 21 7 738
233. Meta-analysis of randomized clinical trials on β-blocker treatment in heart failure. Léchât PP, Chalon S, Cucherat M, Packer M, Boisse! JP CIRCULATION 1996 94 8 Suppl 1665
234. Pharmacophores of the dual acting o,β-blockers as deduced from molecular dynamics simulations. Kamath S, Coutinho E J B1OSC11996 21 5 599, 611
235. Novel drugs and current therapeutic approaches in the treatment of heart failure. Bonarjee WS, Dickstein K DRUGS 1996 51 3347-358
236. Pharmacologie treatment of congestive heart failure. Carson P CLIN CARDIOL 199619 4 271-277
237. Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Schmilz W, Boknik P, LJnck B, Muller FU MOL CELL BIOCHEM1996157 1 -2 251 -258
238. [Modern management of cardiac insufficiency: Role of Carvedilol]. TRATAMIENTO ACTUAL DE LA INSUFICIENCIA CARDIACA: PAPEL DEL CARVEDILOL Bayes G, Guindo J, Tomas L, Garcia Moll M. Bayes Deluna A REV LAT CARDIOL EUROAMERICANA 199617 5 181-184
239. How and to what extent has β-blocker treatment been established for chronic heart failure?. Yokota Y J CARDIOL 1996 28 299-112
240. Optimal management of heart failure. Hsu I J AM PHARM ASSOCIATION 1996 36 2 92-106
241. Meta-analysis of β-blocker therapy in heart failure. Léchât P, Chalon S, Cucherat M, Packer M, Boissel JP EUR HEART J1996 17 Abstr Suppl 79
242. Current perspectives on β-receptor antagonists in the treatment of symptomatic ventricular dysfunction. Adams JRKF PHAFIMACOTHERAPY199616 2 II 69S-77S
243. [Left ventricular systolic dysfunction in the cardiomyopathies]. DYSFUNCTION VENTRICULAIRE SYSTOLIQUE DANS LES MYOCARDIOPATHIES. Bouhour JB, Langlard JM ARCH MAL COEUR VAISS1996 89 Spec. Iss 2 33-37
244. Pathophysiology of heart failure: Changing perceptions. Patterson JH, Adams JRKF PHARMACOTHERAPY1996 16 2 II 27S-36S
245. β-Blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease. Packer M EUR HEART J1996 17 Suppl B 21-23
246. β-Blockers in heart failure - The evidence from clinical trials. Hampton JR EUR HEART J199617Suppl B 17-20
247. [Report from the Annual Meeting of the American College of Cardiology: Which drugs for the treatment of heart failure?]. BERICHTE VON DER JAHRESTAGUNG DES AMERICAN COLLEGE OF CARDIOLOGY: WAS HILFT DEM HERZ AUF DIE SPRUNGE?. MUNCH MED WOCHENSCHR1996138 1516-17
248. [Treatment of heart failure with β-blockers]. THERAPIE DER CHRONISCHEN HERZINSUFFIZIENZ MIT βREZEPTORENBLOCKERN. Bohm M Z KARD1OL 1996 85 Suppl. 7 11-21
249. [Pharmacology of β-receptor blockers]. PHARMAKOLOGIE VON .beta.-REZEPTORENBLOCKERN. Schmilz W Z KARDIOL 1996 85 Suppl 7 5-9
250. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Krum H, Sackner Bernstein JD, Goldsmith RL, Kukin ML, Schwarte B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M CIRCULATION 1995 92 61499-1506
251. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. Sackner BERNSTEINJD, Mancini DM JAMMEDASSOC1995 274 18 1462-1467
252. Role of β-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. White M, Yanowitz F, Gilbert EM, Larrabee P, O'Connel! JB, Anderson JL, Renlund D, Mealey P, Abraham WT, Bristow MR AMJCARDIOL1995 76 17 1271-1276
253. Design of the β-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. Anonymous AM J CARDIOL 1995 75 17 1220-1223
254. [β-Blockers in the treatment of chronic heart failure]. BETABLOCKKEERDERS IN DE BEHANDEUNG VAN CHRONISCH HARTFALEN. Van Cleemput J, Vanhaecke J TIJDSCHR GENEESKD 199551 12883-888
255. [Beta-blockers in chronic heart failure]. BETAREZEPTORENBLOCKER BEI CHRONISCHER HERZINSUFFIZIENZ. Sigmund M, Hanrath P Z KARDIOL 1995 84 10 820-826
256. Bucindolol hydrochloride. DRUGS FUTURE 1995 20 7 719
257. [β-Blockers and heart failure]. BETABLOQUANTS ADRENERGIQUES ET INSUFFISANCE CARDIAQUE. Lechat P ARCH MAL COEUR U4/SS1995 88 4 Suppl. 611-615
258. Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. Heesch CM, Marcoux L, Hatfield B, Eichhorn EJ AM J CARDIOL 1995 75 5 360-364
259. The role of β-blockers in congestive heart failure. Welter EA, Semchuk WM CAN J HOSP PHARM1995 48 6 328-335
260. [Use of β-blockers in congestive heart failure]. . BETABLOCKER BEI HERZINSUFFIZIENZ. Noll G SCHWEIZ RUNDSCH MED PRAX1995 84 11 313-318
261. Use of β-adrenoceptor blockers in patients with congestive heart failure. Panfilov V, Wahlqvist I, Olsson G CARDIOVASC DRUGS THER1995 9 2 273-287
262. β-Adrenergic blockers and CHF: More rest for the weary. Katz RJ BRI J CARDIOLOGY 1995 2 9 251 -254
263. Adrenergic β-blocking agents in congestive heart failure due to idiopathic dilated cardiomyopathy. Waagstein F EUR HEART J1995 16 Suppl O 128-132
264. What patients with congestive heart failure respond to beta-blocking agents: A Meta-Analysis. White M, Gilbert EM, Anderson J, O'Connell JB, Renlund D, Olsen S, Mealy P, Abraham WT, Rouleau JL, Bristow MR J HEART LUNG TRANSPLANT 1995 141PI2S85
265. [Chronic heart failure, sympathetic nervous system and beta-blockers]. INSUFFICIENZA CARDIACA CRONICA, SISTEMA NERVOSO SIMPATICO E BETA-BLOCCO. Carelli M, Di Marcotullio G, Becchis A CUORE1995 12 1 69-81
266. [The use of β-blockers in the therapy of congestive heart failure]. LA UTILIDAD DE LOS BETABLOQUEANTES EN EL MANEJO DEL FALLO CARDIACO CONGESTIVO. Ortiz Demurua JA, Villafranca JL, Avila MC. Del CAM POP CLIN CARDIOVASC 1995 13 2 55-64
267. New medical therapies for advanced left ventricular dysfunction. Baughman K CARDIOL CL/A/1995 13 1 27-34
268. Improvement in cardiac myocyte function by biological effects of medical therapy: A new concept in the treatment of heart failure. Bristow MR, Gilbert EM EUR HEART J 1995 16 Suppl. F 20-31
269. Carvedilol update III: Rationale for use in congestive heart failure. Feuerstein GZ, Poste G, Ruffolo RRJR DRUGS TODAY 1995 31 Suppl. F 1-23
270. β-Blocker treatment for chronic heart failure: The frog prince. Eichhorn EJ, Hjalmarson A CIRCULATION 1994 90 4 2153-2156
271. Choosing the right β-blocker: A guide to selection. Hampton JR DRUGS 1994 48 4 549-568
272. Clinical relevance of inverse agonism and guanine nucleotide modulatable binding properties of β-adrenergic receptor blocking agents. Lowes BD, Chidiac P, Olsen S, Port JD, Bouvier M, Gilbert EM, Bristow MR CIRCULATION 1994 90 4 Pt 2 I543
273. Does gender affect the response to medical therapy in heart failure? Lindenfeld J, Gilbert EM, Abraham WT, Olsen S, Wolfel E, Bristow MR CLIN RES 1994 42 2 323A
274. [β-Blockade treatment in heart failure]. BETABLOQUANTS ET INSUFFISANCE CARDIAQUE. Léchât P THERAPIE 1994 49 3 219-224
275. Cardiac transplantation: 1. From CHF to surgery. Renlund DG, Gunnar RM HOSP PRACT 1994 29 11 71-75+79-80+83
276. The treatment of heart failure - What next? Davies RH, Sheridan DJ BR J CLIN PHARMACOL1993 35 6 557-563
277. The importance of left ventricular diastolic dysfunction and right ventricular performance in the heart failure syndrome. Udelson JE, Surks H, Konstam MA CURR OPIN CARD1OL 1993 8 3 383-396
278. Should patients with idiopathic dilated cardiomyopathy fail β-blocker therapy prior to cardiac transplantation? Olsen SL, Blank D, Taylor DO, Gilbert EM, Mealey PC, O'Connell JB, Renlund DG CIRCULATION 1993 88 4 R 2 I93
279. Controlled trials with β-blockers in heart failure: Metoprolol as the prototype. Fowler MB AM J CARD1OL1993 71 9 45C-53C
280. The role of calcium antagonists in the treatment of chronic heart failure. Parameshwar J, Poole WILSONPA EUR HEART J 1993 14SupplA38-44
281. Beta blockers in heart failure. Waagstein F CARDIOLOGY 199382SuppI313-18
282. β-Blockers in congestive heart failure: A meta-analysis and other literature data. Cinteza M, Vinereanu D, Corian A, Balanescu S, Gherasim L EUR HEART J199314 AbstrSupp110
283. β-Blockers and the failing heart: Is it time for a U-turn? Bashir Y, McKenna WJ, Camm AJ BR HEART J1993 70 1 8-12
284. β-Blocking agents with vasodilator activity. Rosendorff C J HYPERTENS199311 Suppl 4 S37-S40
285. Redux costs Interneuron S10.8 million SCRIP 1998 230011 277817 Knoll's R&D expectations SCRIP 1998 2307 13
286. Intercardia gains rights to heparin-derived oligosaccharide for IBD EMERGING PHARMACEUTICALS1998 7 5 6
287. Intercardia announces second quarter results Intercardia Inc PRESS RELEASE 1998 May 5
288. Stockholders approve Transcell merger with Intercardia Intercardia Inc PRESS RELEASE 1998 May 6
289. Intercardia announces initiation of European trial for Bextra. Intercardia Inc PRESS RELEASE 1998 June 25
290. Intrinsic sympathetic activity in normal and heart failure rats: xamoterol, bucindolol and carvedilol Willette R, Mitchell M, Anderson K, et al J MOL CELL CARDIOL 1998 30 91
291. Intercardia begins phase III for heart attack in Europe Intercardia Inc BIOWORLD WEEK 1998 6 27 2
292. Intercardia announces results for third quarter of fiscal 1998 Intercardia Inc PRESS RELEASE 1998 August 14
293. Determination of bucindolol and its major metabolites in plasma by capillary gas chromatography/mass spectrometry. Bartek MJ, Kems EH, Gammans RE, Gallo DG J CHROMATOGR1986 377183-194
294. Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart Wilette R N, Mitchell M P, Ohlstein EH, Lukas MA, Ruffolo RR PHARMACOLOGY 1988 56 3036
295. A review of why and how we may use β-blockers in congestive heart failure. Constant J CHEST 1998 113 800-880
296. The role of the neurohormonal system in heart failure, Komajda M, Pousset F, Isnard R, Lechat P HEART 1998 79 Suppl 2 S17-S23
297. β-Adrenoceptor blockade in congestive heart failure: future perspectives. Poole-Wilson PA HEART 1998 79 Suppl 2 S35-S36
298. Intercardia and Astra Pharmaceuticals end agreement for collaboration on Bextra competing product arises from corporate restructuring of Astra Merck Intercardia Inc PRESS RELEASE 1998 September 30
299. Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity. Kreighbaum WE, Lesley Malier M, Dennis RD, Minielli JL, Deitchman D, Perhach JL, Comer WT J MED CHEM1980 23 3 285-289
300. Chemical and SAR study on indole derivatives of phenoxypropanolamines.
301. Chemistry of a and βadrenoceptor agonists and antagonists. Phillips DK HANDBOOK EXP PHARMACOL 1980 54 1
302. Bucindolol Deitchman D, LaBudde JA, Seidehamel RJ NEW DRUGS ANNUAL: CARDIOVASCULAR DRUGS 198111-18
303. Astra returns US rights for CHF drug to Intercardia BIOWORLD WEEK 1998 6 40 4
304. Intercardia announces fiscal year 1998 results Intercardia Inc PRESS RELEASE 1998November 06
305. Intercardia reports data and safety monitoring board recommends continuation of bucindolol study enrollment to end December 31, 1998 Intercardia Inc PRESS RELEASE 1998 November 11
306. DRUG DEV PIPELINE 1998 381-4